| The utility of sulfonate salts in drug development. | |
| | |
MedLine Citation:
|
PMID: 20112423 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The issue of controlling genotoxic impurities in novel active pharmaceutical ingredients (APIs) is a significant challenge. Much of the current regulatory concern, has been focused on the formation and control of genotoxic sulfonate esters. This is linked with the withdrawal of Viracept (Nefinavir mesilate) from European markets in mid-2007, over concerns about elevated levels of ethyl methanesulfonate (EMS). This issue has resulted in calls from European regulators to assess risk mitigation strategies for all marketed products employing a sulfonic acid counter-ion to ensure that the sulfonate esters that could be potentially formed are controlled to threshold of toxicological concern (TTC)-based limits. This has even led to calls to avoid sulfonic acids as salt counter-ions. However, sulfonic acid salts possess a range of properties that are useful to both synthetic and formulation chemists. Whilst sulfonate salts are not a universal panacea to some of the problems of salt formation they do offer significant advantages as alternatives to other salt forming moieties under certain circumstances. This review thus sets out to define some of the advantages provided through utilization of sulfonic acids, explaining the importance of their retention as part of a thorough salt selection process. |
| | |
Authors:
|
David P Elder; Ed Delaney; Andrew Teasdale; Steve Eyley; Van D Reif; Karine Jacq; Kevin L Facchine; Rolf Schulte Oestrich; Patrick Sandra; Frank David |
Related Documents
:
|
10896953 - Extreme halophiles synthesize betaine from glycine by methylation. 8486783 - Renal acid excretion and intracellular ph in salt-sensitive genetic hypertension. 6435443 - A comparative study of the efficiency of intragastric and parenteral nutrition in man. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of pharmaceutical sciences Volume: 99 ISSN: 1520-6017 ISO Abbreviation: J Pharm Sci Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-04-30 Completed Date: 2010-08-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 2985195R Medline TA: J Pharm Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 2948-61 Citation Subset: IM |
Copyright Information:
|
(c) 2010 Wiley-Liss, Inc. and the American Pharmacists Association |
Affiliation:
|
GlaxoSmithKline Research and Development, Park Road, Ware, Hertfordshire SG12 0DP, United Kingdom. david.p.elder@gsk.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Drug Discovery* Humans Salts / chemistry*, pharmacology Sulfonic Acids / chemistry*, pharmacology |
| Chemical | |
Reg. No./Substance:
|
0/Salts; 0/Sulfonic Acids |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dimerization of protein G B1 domain at low pH: A conformational switch caused by loss of a single hy...
Next Document: 5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepat...